Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $67.15 | Total: $335.75 |
| 1 | 10 | $56.88 | Total: $568.80 |
| 1 | 25 | $48.19 | Total: $1,204.75 |
| 1 | 50 | $41.08 | Total: $2,054.00 |
| 1 | 100 | $35.55 | Total: $3,555.00 |
Overview
EOC317 (ACTB-1003) is an oral kinase inhibitor with IC50 values of 6 nM, 2 nM, and 4 nM for FGFR1, VEGFR2, and Tie-2, respectively.
Chemical Properties
| Molecular Formula | C27H26F5N7O3 |
| Molecular Weight | 591.53 |
| CAS Numbers | 939805-30-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COCc1c(CN2CCOCC2)n2ncnc(N)c2c1-c1ccc(NC(=O)Nc2cc(ccc2F)C(F)(F)F)c(F)c1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Patel K, et al. ACTB-1003 An oral kinase inhibitor targeting cancer mutations [FGFR], angiogenesis [VEGFR2, TEK], and induction of apoptosis [RSK and p70S6K]. Journal of Clinicalal Oncology 28, no. 15 DOI 10.1200jco.2010.28.15_suppl.e13665